Bausch + Lomb Receives CE Mark for Luxlife Intraocular Lens, Expanding European Ophthalmology Portfolio

Bausch + Lomb, a leading global eye health company, has secured a CE mark for its Luxlife intraocular lens (IOL), paving the way for its launch in Europe in the coming weeks. This development marks a significant expansion of the company's ophthalmology portfolio and offers new options for patients undergoing cataract surgery.

Luxlife IOL: Advanced Technology for Full Range Vision

The Luxlife IOL is designed to support near, intermediate, and far vision, addressing a common challenge faced by cataract patients. Unlike diffractive full range of vision IOLs, the Luxlife lens employs non-diffractive technology that ensures no light loss to the retina, potentially improving overall visual outcomes.

Yehia Hashad, Chief Medical Officer at Bausch + Lomb, highlighted the technological distinctions between the company's Lux and Envista lens platforms. "Lux lenses have a slightly different platform than the Envista because they use a different optical design diffractive technology," Hashad explained during a recent earnings call.

Clinical Trial Results and Patient Benefits

The CE mark approval was supported by a clinical trial conducted by Cutting Edge, a French IOL developer. The study compared the trifocal Luxlife IOL to Bausch + Lomb's monofocal Luxgood lens. Results demonstrated excellent binocular visual outcomes at all distances for Luxlife recipients. Notably, 89.5% and 95.6% of Luxlife users reported being able to see without glasses at near and intermediate distances, respectively.

Bausch + Lomb plans to initially launch a non-toric version of the Luxlife lens, followed closely by a toric version designed to correct astigmatism. This phased approach will allow the company to address a broader range of patient needs in the European market.

Strategic Expansion and Future Outlook

The introduction of the Luxlife IOL is part of Bausch + Lomb's broader strategy to strengthen its position in the European ophthalmology market. CEO Brent Saunders, speaking on a recent earnings call, outlined upcoming milestones for the company, including the Luxlife launch and plans for a soft launch of Envista Envy in Europe later this year, with a full rollout expected in early 2026.

This expansion comes in the wake of recent challenges faced by the company's Envista IOL line in the United States. Some Envista lenses were temporarily recalled due to inflammatory reactions, but have since returned to the market after the company identified a raw material from a vendor as the cause of the issue.

As Bausch + Lomb continues to innovate and expand its product offerings, the Luxlife IOL represents a significant step forward in addressing the diverse needs of cataract patients across Europe.